Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACellDREAM2: Autologous ASC in Critical Limb Ischemia
NCT03968198Phase 2Terminated
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Mar 2020
- Primary completion
- Mar 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in critical limb ischemia (CLI), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Number of patients alive without major amputation and without critical limb ischemia at 6 months. Started Mar 2020; status: terminated.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT03968198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03968198.